7 Most Undervalued Biotech Stocks To Invest In
On February 21, Jared Holz, Mizuho Securities America's healthcare sector strategist, appeared on CNBC to discuss Trump's tariffs and their effects on the American pharma sector.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 1,609,899 | $246,185,755 | +271% | 0.18% |
| 2. | Renaissance Technologies Jim Simons | 1,192,206 | $182,312,142 | +26% | 0.26% |
| 3. | GLG Partners Noam Gottesman | 686,550 | $104,987,225 | -20% | 0.27% |
| 4. | Millennium Management Israel Englander | 543,844 | $83,164,624 | +37% | 0.04% |
| 5. | AQR Capital Management Cliff Asness | 539,692 | $81,914,391 | +982% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $222.54 | 455 | Director | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | Director | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | Officer, Director | 34,810 | 2020-11-30 | Filing | |
| $231.24 | 38,000 | Director | 643,000 | 2019-05-02 | Filing | |
| $229.46 | 30,000 | Director | 605,000 | 2019-05-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $150.02 | 8,760 | Director | 11,318 | 2025-03-07 | Filing | |
| $157.21 | 110 | Officer | 5,426 | 2024-12-09 | Filing | |
| $204.22 | 431 | Officer | 5,316 | 2024-09-03 | Filing | |
| $213.09 | 93 | Officer | 4,886 | 2024-04-02 | Filing | |
| $221.23 | 262 | Officer | 4,886 | 2024-02-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,748,875 | $2,561,237,965 | 0.04% | |
| 2. | 16,046,209 | $2,453,786,283 | 1.9% | |
| 3. | 15,473,710 | $2,366,239,663 | 0.04% | |
| 4. | 7,398,248 | $1,131,229,765 | 0.04% | |
| 5. | 4,930,723 | $754,006,161 | 0.13% |
News See All
15 Stocks That Will Go to The Moon According to Analysts
While stocks initially fell based on worries regarding Trump tariffs on America’s major trading partners, major indexes recovered from their initial losses as the President delayed tariffs on Mexico...
10 Cheap Pharmaceutical Stocks to Buy According to Analysts
Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of companies that provide patient care, research and development of new medicines...
Biogen Inc. (NASDAQ:BIIB) Q4 2024 Earnings Call Transcript
Operator: Good morning. My name is Jennifer and I will be your conference operator today.
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
12 Best S&P 500 Stocks to Invest in According to Analysts
2024 was a memorable year for the broad market index, which posted a gain of 23.31%, building on the 24.2% return in 2023.
Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently
Jim Cramer, the host of Mad Money, recently shared his perspective on the stock market, especially reflecting on the events of 2024.
12 Cheap Healthcare Stocks to Buy Heading into 2025
Investing in healthcare equities is typically seen as protective during recessionary times.
10 Worst Performing Healthcare Stocks in 2024
The healthcare industry remains a vital and resilient sector which is driven by advancements in technology, increasing global demand, and an aging population.